Benevich Eric's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Feb 15, 2024
- Accession no.
- 0000914475-24-000068
- Filed
- Feb 15, 2024
- Trade date
- Feb 13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 2 derivative transactions. Open-market sales total $146.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Benevich EricCIK 0001643653 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | Common Stock | SSaleDisposed | −1,098 | $133.01 | −$146,044.98 | 40,616 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 13, 2024 | Common Stock | AGrant or awardAcquired | +39,426 | $0.00 | $0 | 39,426 | Direct | |
| Feb 13, 2024 | Common Stock | AGrant or awardAcquired | +7,846 | $0.00 | $0 | 7,846 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.